Acting Attorney General Todd Blanche dropped a bombshell Thursday. The Justice Department is now rescheduling marijuana from Schedule I to Schedule III under federal law. This fulfills a promise from President Donald Trump made over four months ago and opens doors for better medical research and patient care nationwide.12
Marijuana sat in Schedule I for decades. That group includes drugs like heroin with no accepted medical use and high abuse risk. Schedule III changes everything by recognizing marijuana’s medical value with moderate abuse potential. Think drugs like codeine or ketamine.
This shift does not legalize recreational use. Federal rules still ban it outside medical channels. But state-licensed medical products and FDA-approved ones now fall under lighter controls.
Doctors gain tools to study it better. Patients could see new treatments soon.
Timeline from Trump Order to Action
President Trump signed an executive order on December 18, 2025. It pushed the Justice Department to speed up the process. Blanche quoted Trump in his announcement. “The Department of Justice is delivering on President Trump’s promise to expand Americans’ access to medical treatment options,” he said.
This rescheduling action allows for research on the safety and efficacy of this substance. It took over four months amid talks of delays. Trump even urged officials last week to stop slow-walking it.
The order targets medical marijuana products right away. Full rollout needs more steps but moves fast.
Boost for Medical Research and Patients
Research on marijuana faced huge hurdles as a Schedule I drug. Labs needed special licenses. Funding stayed scarce. Now Schedule III eases that.
A 2023 FDA review found support for medical uses like pain relief. Studies could explode. Early data shows promise for chronic pain and epilepsy.
Patients win big. Better care means options beyond pills with harsh side effects. Doctors get clear guidance.
One sentence sums it up. Lives could improve through science.
Industry Changes and Economic Impact
Cannabis businesses cheer the loudest. Section 280E tax rule ends, letting firms deduct normal costs like rent and wages. Before, they paid up to 70% effective tax on revenue.
US cannabis sales hit $42 billion last year. Projections show growth to $52 billion in 2026 per industry reports. Medical side leads with $14.5 billion in 2025, eyeing $41 billion by 2031.
Banking opens up too. Firms shunned pot money over federal risks. Now loans flow easier.
| Aspect | Before (Schedule I) | After (Schedule III) |
|---|---|---|
| Tax Deductions | No business expenses | Full deductions allowed |
| Research Access | Very restricted | Easier approvals |
| Banking | High risk, few services | Safer for lenders |
| Medical Recognition | None accepted | Moderate medical use OK |
What Stays the Same and Lingering Hurdles
Recreational sales remain illegal federally. States with legal markets like 24 for rec use keep operating. But conflicts linger.
Critics worry about youth access or over-medicalizing. Groups like Smart Approaches to Marijuana plan court fights. They call it bad policy.
No big shift for past convictions yet. Criminal justice reform sits on hold.
States lead. Nearly 38 allow medical cannabis. This aligns federal rules closer.
This pivotal step marks a turning point after 50 years of strict bans. Patients stand to gain real relief from proven treatments while businesses breathe easier without crippling taxes. Research will uncover more benefits, touching millions facing pain or illness. America feels hope in this balanced reform.
